{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:33:56Z","timestamp":1783578836109,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004397","name":"Ministry of Public Health","doi-asserted-by":"publisher","award":["HITAP.F-2562-000"],"award-info":[{"award-number":["HITAP.F-2562-000"]}],"id":[{"id":"10.13039\/501100004397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009210","name":"Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.vhri.2022.10.005","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T12:01:27Z","timestamp":1669982487000},"page":"40-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Cost-Utility Analysis of Biologic Disease-Modifying Antirheumatic Drugs for Patients With Psoriatic Arthritis in Thailand"],"prefix":"10.1016","volume":"34","author":[{"given":"Piyameth","family":"Dilokthornsakul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratree","family":"Sawangjit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manathip","family":"Osiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveena","family":"Chiowchanwisawakit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Worawit","family":"Louthrenoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unchalee","family":"Permsuwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vhri.2022.10.005_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","article-title":"Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis","volume":"48","author":"Scotti","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"suppl 2","key":"10.1016\/j.vhri.2022.10.005_bib2","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"suppl 1","key":"10.1016\/j.vhri.2022.10.005_bib3","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","article-title":"Treatment guidelines in psoriatic arthritis","volume":"59","author":"Ogdie","year":"2020","journal-title":"Rheumatol (Oxf Engl)"},{"issue":"6","key":"10.1016\/j.vhri.2022.10.005_bib4","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/11533010-000000000-00000","article-title":"Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis","volume":"28","author":"Adams","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.vhri.2022.10.005_bib5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3899\/jrheum.190083","article-title":"Evaluation of the economic burden of psoriatic arthritis and the relationship between functional status and healthcare costs","volume":"47","author":"McHugh","year":"2020","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.vhri.2022.10.005_bib6","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1201450","article-title":"The CEDAR study: a longitudinal study of the clinical effects of conventional DMARDs and biologic DMARDs in Australian rheumatology practice","volume":"2017","author":"Roberts","year":"2017","journal-title":"Int J Rheumatol"},{"issue":"3","key":"10.1016\/j.vhri.2022.10.005_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.vhri.2022.10.005_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.vhri.2022.10.005_bib10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12962-018-0162-3","article-title":"Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active psoriatic arthritis: a Finnish perspective","volume":"16","author":"Purmonen","year":"2018","journal-title":"Cost Eff Resour Alloc"},{"issue":"2","key":"10.1016\/j.vhri.2022.10.005_bib11","first-page":"163","article-title":"Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective","volume":"21","author":"Goeree","year":"2018","journal-title":"J\u00a0Med Econ"},{"issue":"6","key":"10.1016\/j.vhri.2022.10.005_bib12","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1017\/S0266462319000321","article-title":"Health technology assessment in Thailand: institutionalization and contribution to healthcare decision making: review of literature","volume":"35","author":"Leelahavarong","year":"2019","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.vhri.2022.10.005_bib13","author":"Perez"},{"key":"10.1016\/j.vhri.2022.10.005_bib14","series-title":"Guidelines for Health Technology Assessment in Thailand","author":"Chaikledkaew","year":"2009"},{"key":"10.1016\/j.vhri.2022.10.005_bib15","series-title":"Guidelines for Health Technology Assessment in Thailand","author":"Chaikledkaew","year":"2013"},{"issue":"56","key":"10.1016\/j.vhri.2022.10.005_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21560","article-title":"Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation","volume":"21","author":"Corbett","year":"2017","journal-title":"Health Technol Assess"},{"issue":"11","key":"10.1016\/j.vhri.2022.10.005_bib17","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2217\/cer-2018-0075","article-title":"Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics\/apremilast: a network meta-analysis","volume":"7","author":"McInnes","year":"2018","journal-title":"J\u00a0Comp Eff Res"},{"issue":"10","key":"10.1016\/j.vhri.2022.10.005_bib18","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/art.1780401021","article-title":"Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death","volume":"40","author":"Wong","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.vhri.2022.10.005_bib19","author":"Riewpaiboon"},{"issue":"5","key":"10.1016\/j.vhri.2022.10.005_bib22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/14737167.2018.1494574","article-title":"The EQ-5D-5L valuation study in Thailand","volume":"18","author":"Pattanaphesaj","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"10.1016\/j.vhri.2022.10.005_bib23","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar2796","article-title":"Comprehensibility, reliability, validity, and responsiveness of the Thai version of the Health Assessment Questionnaire in Thai patients with rheumatoid arthritis","volume":"11","author":"Osiri","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"suppl 2","key":"10.1016\/j.vhri.2022.10.005_bib24","doi-asserted-by":"crossref","first-page":"ii65","DOI":"10.1136\/ard.2004.031237","article-title":"Psoriasis assessment tools in clinical trials","volume":"64","author":"Feldman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vhri.2022.10.005_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/CEOR.S38062","article-title":"Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?","volume":"5","author":"Thavorncharoensap","year":"2013","journal-title":"Clinicoecon Outcomes Res"},{"issue":"5","key":"10.1016\/j.vhri.2022.10.005_bib26","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40273-018-0618-5","article-title":"Cost and cost effectiveness of treatments for psoriatic arthritis: a systematic literature review","volume":"36","author":"D\u2019Angiolella","year":"2018","journal-title":"Pharmacoeconomics"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109922001923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109922001923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:14:07Z","timestamp":1761941647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109922001923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":23,"alternative-id":["S2212109922001923"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2022.10.005","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Utility Analysis of Biologic Disease-Modifying Antirheumatic Drugs for Patients With Psoriatic Arthritis in Thailand","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2022.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}